Night Jessamine (Cestrum nocturnum L.): A Comprehensive Reference
1. Identity: Botanical Classification, Names, and Natural Source
1.1 Taxonomic Position and Botanical Names
Cestrum nocturnum, common names include night-blooming jasmine, night-blooming cestrum, and raatrani, is a species of Cestrum in the plant family Solanaceae (the potato family). Despite its widespread popular name "night jessamine" or "night-blooming jasmine," it is absolutely not a true jasmine and bears no botanical relationship to plants in the Jasminum genus. This fragrant shrub belongs to the Solanaceae family (nightshades), making it more closely related to tomatoes, potatoes, and tobacco than to actual jasmines, which are members of the Oleaceae family. The confusion arises from the plant's intensely sweet, jasmine-like fragrance that it releases during nighttime hours, leading to the misleading common name.
The scientific name Cestrum nocturnum has been cited in botanical literature since the 18th century, having been described by Carl Linnaeus in 1753. The genus name Cestrum originates from the Greek kestron, meaning 'point' or 'engraving tool', a term used by Dioscorides for aromatic plants. The specific epithet nocturnum comes from Latin and refers to the flowering habit and release of perfume at night.
1.2 Common Names
- Night-Blooming Jessamine, Night-Blooming Jasmine, Night-Blooming Cestrum, Raatrani, Queen of the Night, Night Jessamine, Lady of the Night.
- In Spanish: dama de noche; in German: Nachtjasmin; in French: cestreau nocturne; in Urdu: raat ki rani.
1.3 Morphology and Natural Source
Cestrum nocturnum is an evergreen woody shrub with slender branches growing to 4 m (13 ft) tall. The plant is multi-branched and heavily foliated. Its leaves are simple, narrow lanceolate, 6–20 cm (2.4–7.9 in) long and 2–4.5 cm (0.79–1.77 in) wide, with a smooth glossy surface and an entire margin. Its slender, tubular, creamy white to pale green flowers open after dusk and release a sweet, musky perfume that can travel remarkably far in warm, still air.
It is native to Mexico, Central America, and northern South America and is naturalized in South Asia. Cestrum nocturnum has become widely naturalized in tropical and subtropical regions throughout the world, including Australia, New Zealand, South Africa, southern China, and the southernmost United States, and is difficult to eradicate. This plant has escaped cultivation and is considered to be an aggressive weed or invasive in many parts of Oceania, including Australia, New Zealand, Fiji, French Polynesia, New Caledonia, and Samoa.
1.4 Common Preparations and Dosage Forms
Cestrum nocturnum is encountered in several forms in traditional and contemporary contexts. These include:
- Leaf decoctions and extracts: In traditional Mexican medicine, extracts from the leaves are used as antispasmodics, particularly in the alternative treatment of epilepsy, although such uses are limited by the species' inherent toxicity.
- Hydroalcoholic and methanolic extracts: Used in laboratory research. Cestrum nocturnum leaves extract in hydroalcoholic solution prepared by Soxhletation method has been used in animal experiments; Wistar rats were made diabetic by a single dose of streptozotocin (150 mg/kg i.p.), and the extract was given at a concentration of 200 mg/kg and 400 mg/kg of body weight.
- Essential oil (flower-derived): Flowers distilled oil contains phenylethyl alcohol (27%), benzyl alcohol (12%), eicosane (5.6%), eugenol (5.6%), n-tetracosane (4.4%), caryophyllene oxide (3.1%), 1-hexadecanol (2.7%), methoxyeugenol (2.45%), benzaldehyde (2.32%).
- Chinese leaf preparations: The leaves are used in Chinese folk medicine as an external application for burns and swellings.
2. Traditional and Historical Uses
2.1 Mesoamerican and Caribbean Traditions
C. nocturnum is native to Mexico, Central America, and northern South America. Within these regions, it has a documented history of ethnobotanical use. In traditional Mexican medicine, extracts from the leaves are used as antispasmodics, particularly in the alternative treatment of epilepsy. Accounts note that leaf extracts of the plant were used by ancient Mesoamerican peoples in antispasmodic preparations, against skin eruptions, and in the management of seizure conditions.
2.2 South and East Asian Traditions
C. nocturnum has long been used in traditional Chinese medicine (TCM) to treat digestive diseases for centuries. In Chinese traditional medicine, the leaves of C. nocturnum have been used to cure a variety of ailments.
In Thailand, the leaves are considered toxic to humans, but they may be used in small doses to treat epilepsy. The leaves are used in Chinese folk medicine as an external application for burns and swellings.
The plant is also embedded in South Asian traditions, particularly in India, where it is known as raat ki rani (Queen of the Night) and raatrani. It is native to the West Indies but naturalized in South Asia.
2.3 Shamanic and Ritualistic Use
In a rare discussion of traditional entheogenic use of the plant, Müller-Ebeling, Rätsch, and Shahi describe shamanic use of C. nocturnum in Nepal, describing "trippy" effects without mentioning unpleasant physical side effects. Rätsch's Encyclopedia of Psychoactive Plants also describes a handful of reports of ingestion of the plant without mentioning serious adverse side effects. The mechanisms of the plant's putative psychoactive effects are currently unknown, and anecdotal data are extremely limited and include an aphrodisiac power.
Ethnobotanical records document the ritualistic use of the plant by shamans in Nepal, who report mild psychoactive effects in spiritual experiences, practices that are rare and little studied scientifically.
2.4 Summary of Traditional Preparations by Region
- Mexico / Mesoamerica: Leaf extracts as antispasmodics and antiepileptic preparations.
- China: Used in traditional Chinese medicine to treat digestive diseases for centuries.
- Thailand: Small doses of leaf preparations for epilepsy.
- China (topical): Leaf applications for burns and swellings.
- Nepal: Ritualistic use with reported psychoactive effects.
3. Key Chemical Constituents and Established Mechanisms of Action
3.1 Phytochemical Overview
The results indicate that Cestrum nocturnum contains a range of phytochemicals, such as alkaloids, glycosides, flavonoids, and essential oils. Systematic phytochemical screening has revealed a rich and diverse chemical profile:
- Steroidal saponins and glycosides: Among the most thoroughly characterized class of compounds. Phytochemical analysis of the leaves of Cestrum nocturnum (Solanaceae) resulted in the isolation of two new flavonol glycosides and seven steroidal saponins, including four new ones. Further phytochemical analysis aimed at the steroidal glycoside constituents of the leaves of Cestrum nocturnum resulted in the isolation of eight new steroidal glycosides, which were classified into a spirostanol saponin, a furostanol saponin, a pseudo-furostanol saponin, two pregnane glycosides, two cholestane glycosides, and a pregnane-carboxylic acid gamma-lactone glycoside.
- Pennogenin tetraglycoside: Antifungal assay-guided fractionation of the methanolic crude extract of Cestrum nocturnum led to the isolation and identification of the steroidal saponin named pennogenin tetraglycoside, which was identified for the first time in this plant species by spectroscopic means.
- Alkaloids: Cestrum nocturnum leaves contain alkaloids such as nicotine and solanine. The leaves of Cestrum nocturnum contain atropine-like anticholinergic alkaloids. The unripe berries contain solanine, while the ripe berries contain anticholinergic glycoside toxins.
- Flavonoids: Several bioactive phytoconstituents such as flavonoids, glycosides, tannins, coumarins, anthocyanins, sapogenins, and sterols have been identified. Fractionation studies have specifically identified rutin and quercetin as flavonoid compounds present in Cestrum nocturnum.
- Tannins: Tannins are polyphenolic compounds that can have astringent properties. They are found in Cestrum nocturnum leaves and may contribute to their medicinal properties.
- Essential (volatile) oils — flower fraction: The flowers' distilled oil contains phenylethyl alcohol (27%), benzyl alcohol (12%), eicosane (5.6%), eugenol (5.6%), n-tetracosane (4.4%), caryophyllene oxide (3.1%), 1-hexadecanol (2.7%), methoxyeugenol (2.45%), benzaldehyde (2.32%).
- Phenolic compounds: Twelve phenolic compounds were identified and quantified in a methanolic extract of aerial parts of C. nocturnum.
- Cytotoxic steroids: The flower alcohol extract contains cytotoxic steroids.
- Triterpenoids and other compounds: Phytochemical screening identified triterpenoids, alkaloids, flavonoids, saponins, tannins, and steroids.
3.2 Proposed Mechanisms of Action
The diverse phytochemical composition of Cestrum nocturnum is associated with several proposed biological mechanisms, largely derived from in vitro and animal research. No human mechanistic studies have been published.
- Antidiabetic (enzyme inhibition): The methanolic fraction of leaf extracts exhibited strong antioxidant potential against DPPH and ABTS radicals, and strongly inhibited α-amylase (IC50 188.77 ± 1.67 µg/mL) and acetylcholinesterase (AChE) (IC50 239.44 ± 0.93 µg/mL) in a non-competitive and competitive manner, respectively. In silico analysis of compounds identified in the methanolic extract using GC-MS revealed high-affinity binding of these compounds with the catalytic sites of α-amylase and AChE, with binding energy ranging from −3.10 to −6.23 kcal/mol and from −3.32 to −8.76 kcal/mol, respectively, suggesting the antioxidant, antidiabetic, and anti-Alzheimer activity may be driven by the synergistic effect of these bioactive phytoconstituents.
- Anticancer (cytotoxicity / topoisomerase inhibition): The tested fractions attenuated proliferation and induced apoptosis at G0/G1 and G2/M phases in cancer cells through inducing DNA damage and inhibiting topoisomerase II relaxation activity. These results suggest that the fractions may represent important sources of potential antitumor agents due to their pronounced antitumor effects and low immune toxicity.
- Antiepileptic / analgesic (CNS): Repeated administration of five doses, at 1-hour intervals, reduced the amplitude of penicillin-induced epileptic spikes in both primary and secondary foci in curarized rats. The results suggest that C. nocturnum possesses active substances with analgesic activity provided through a peripheral action mechanism, in parallel with some psychoactive activity that does not fit well the neuropharmacological action profile of known reference neurotropic drugs.
- Antifungal (saponin-mediated membrane disruption): The crude extract, fractions, and pennogenin tetraglycoside exhibited mycelial growth inhibition of Fusarium solani and F. kuroshium. Scanning electron microscopy showed morphological alterations of the fungal hyphae after exposure with the active fractions.
4. Scientific Evidence by Area of Use
4.1 Antidiabetic and Antihyperlipidemic Activity
The antidiabetic and antihyperlipidemic activities of C. nocturnum have been reported in rodents. The most directly cited study in this area is:
Kamboj et al. (2013) — Rodent study (Advances in Pharmacological Sciences, PMC3787616): The objective was to investigate antidiabetic activity of hydroalcoholic extract of Cestrum nocturnum leaves in Wistar rats. Wistar rats were made diabetic by a single dose of streptozotocin (150 mg/kg i.p.). Hydroalcoholic leaves extract was given to the STZ-induced diabetic rats at a concentration of 200 mg/kg and 400 mg/kg of body weight in different groups of 6 diabetic rats each, orally once a day for 15 days. The hydroalcoholic extract of plant showed significant (P < 0.01) antidiabetic activity at both doses. This is further evidenced by percentage reduction in blood glucose levels after the 15th day after administering the extract at both doses. The hydroalcoholic extract significantly increased the body weight of diabetic animals at higher doses.
Evidence strength: Weak to preliminary. All published antidiabetic studies are in animal models only; no controlled human clinical trials have been conducted. The streptozotocin (STZ) rat model has well-known limitations in translating to human type 2 diabetes. Group sizes were very small (n=6 per group).
A 2023 study published in Plants (MDPI) evaluated the efficacy of extracts of the leaves of C. nocturnum as potent dual inhibitors of α-amylase and AChE in vitro, finding the methanolic fraction exhibited the strongest antioxidant potential against DPPH (IC50 39.12 ± 0.53 µg/mL) and ABTS (IC50 20.94 ± 0.82 µg/mL) radicals, and strongly inhibited α-amylase (IC50 188.77 ± 1.67 µg/mL) and AChE (IC50 239.44 ± 0.93 µg/mL). These are in vitro findings only.
4.2 Anticancer and Cytotoxic Activity
PMC study (PMC5307125, published 2017 in Evidence-Based Complementary and Alternative Medicine): A previous study first proved that the n-butanol part isolated from the flowers of C. nocturnum produced an inhibitory effect on the proliferation of human hepatocellular carcinoma Bel-7404, human gastric carcinoma SGC-7901, and cervical cancer HeLa cells in a dose-dependent manner. The follow-up study isolated fractions C4 and C5 from the n-butanol part and found: fractions C4 and C5 exhibited great cytotoxicity to cancer cell lines but had low immune toxicity towards T and B lymphocytes in vitro.
The methanolic extract of leaves and stem of Cestrum nocturnum and Cestrum diurnum were investigated for their antioxidant and anticancer attributes through standard methods.
A study on lung cancer cells investigated the cytotoxic effects of Cestrum nocturnum ethanolic extract on A549 lung cancer cells, a type of non-small cell lung cancer (NSCLC). A network pharmacology-based study focused on apigenin, a flavonoid present in the plant's methanolic fraction, uncovering its proposed mechanism of action on hepatocellular carcinoma.
Evidence strength: Preliminary in vitro only. All anticancer evidence is derived from cell line (in vitro) studies. No animal studies or clinical trials in humans have been published. Results from in vitro cancer cell line assays frequently do not translate to clinical efficacy and should be interpreted with caution.
4.3 Anticonvulsant and Central Nervous System Effects
PubMed-indexed animal study (PMID: 18276193): The decoctions were not effective against pharmacologically induced convulsions; however, repeated administration of five doses at 1-hour intervals reduced the amplitude of penicillin-induced epileptic spikes in both primary and secondary foci in curarized rats. The results suggest that C. nocturnum possesses active substances with analgesic activity provided through a peripheral action mechanism, in parallel with some psychoactive activity that does not fit well the neuropharmacological action profile of known reference neurotropic drugs.
Evidence strength: Weak. Animal models only; no human clinical evidence. The pharmacological profile of the active substances responsible for these effects has not been fully elucidated, and the dosing regimen was complex. The anticonvulsant activity observed was partial and preparation-dependent.
4.4 Antifungal Activity
Valencia-MejÃa et al. (2022, Molecules, PMC 8951829): Antifungal assay-guided fractionation of the methanolic crude extract of Cestrum nocturnum led to the isolation and identification of the steroidal saponin pennogenin tetraglycoside, identified for the first time in this plant species; the crude extract, fractions, and pennogenin tetraglycoside exhibited mycelial growth inhibition of Fusarium solani and F. kuroshium. The antifungal activity displayed by pennogenin tetraglycoside against F. kuroshium was highlighted, as it is the first plant natural product identified as active for this phytopathogen.
Evidence strength: Preliminary in vitro/laboratory only. This research is primarily relevant to plant pathology (agricultural fungal disease) rather than human medicine. No studies have evaluated C. nocturnum extracts for the treatment of fungal infections in humans.
4.5 Antimicrobial Activity
The crude methanol extract of C. nocturnum showed remarkable antibacterial activity. The plant has been found to have antibacterial, antioxidative, anti-inflammatory, antifungal, antidiabetic, hepatoprotective, and neuroprotective properties.
Evidence strength: Preliminary in vitro only. Antimicrobial studies of C. nocturnum have been conducted exclusively in laboratory settings using agar diffusion or minimum inhibitory concentration methods. No clinical studies exist.
4.6 Anti-inflammatory and Analgesic Activity
Pharmacological studies have documented anti-inflammatory, analgesic, antimicrobial, anticonvulsant, and sedative properties. These effects have been attributed to the flavonoid, saponin, and alkaloid content of the plant, based on preclinical (in vitro and animal) research. No human clinical trials have evaluated C. nocturnum for pain or inflammation management.
Evidence strength: Weak. Animal and in vitro data only.
4.7 Hepatoprotective Activity
C. nocturnum has garnered the attention of researchers in view of its antioxidative, antimicrobial, antifungal, anti-inflammatory, and hepatoprotective properties. Most flavonoids present in the plant have a hepatoprotective defensive capacity. Hepatoprotective studies have been conducted in animal models; no human data have been published.
Evidence strength: Weak. Preclinical data only.
4.8 Neuroprotective / Anti-Alzheimer's Potential
For the first time, the efficacy of extracts of the leaves of C. nocturnum as potent dual inhibitors of α-amylase and AChE has been evaluated. Acetylcholinesterase (AChE) inhibition is a recognized pharmacological strategy in Alzheimer's disease management. The antioxidant, antidiabetic, and anti-Alzheimer activity of the methanolic extract might be driven by the synergistic effect of bioactive phytoconstituents.
Evidence strength: Highly preliminary. This evidence is exclusively from in vitro enzyme inhibition assays and in silico molecular docking. No animal studies specific to neurodegeneration and no human trials have been published. These results are hypothesis-generating only.
4.9 Overall Evidence Summary
More research is needed, including thorough clinical trials and toxicity assessments, to determine the safety and effectiveness of this treatment for specific conditions. To date, there are no published human (clinical) trials for any therapeutic indication attributed to Cestrum nocturnum. All pharmacological findings are derived from in vitro cell-based systems and small-scale animal models, representing an early stage of scientific investigation. These results cannot be extrapolated to confirm efficacy or safety in humans.
5. Body Systems and Health Areas of Association
Based on preclinical research and traditional use, Cestrum nocturnum has been studied or historically associated with the following body systems. The level of scientific support for each is preliminary and exclusively non-clinical:
- Nervous system / CNS: Anticonvulsant properties in animal models; traditional use for epilepsy; reported psychoactive effects; analgesic activity.
- Endocrine / metabolic (glucose regulation): Antidiabetic activity in rodent models; in vitro α-amylase inhibition.
- Oncology (experimental): Cytotoxicity against several human cancer cell lines (hepatocellular, gastric, cervical, lung) in vitro.
- Immune / infectious disease: Antibacterial and antifungal activities demonstrated in vitro; in vivo larvicidal activity against Aedes aegypti.
- Hepatic (liver): Hepatoprotective properties attributed to flavonoid content in preclinical settings.
- Gastrointestinal: Traditional Chinese medicine application for digestive diseases.
- Respiratory (aromatic/fragrance): Traditional steam inhalation uses; however, the fragrance also acts as a respiratory irritant in sensitive individuals.
- Skin (topical): Traditional use in burns, swellings, skin disorders.
6. Dosages Reported in Studies
The following dosages appear in the published scientific literature. These are reported descriptively as used in experimental settings and do not represent clinical recommendations:
- Antidiabetic study (Kamboj et al., 2013; animal): Hydroalcoholic leaves extract was given to STZ-induced diabetic rats at a concentration of 200 mg/kg and 400 mg/kg of body weight in different groups of 6 diabetic rats each orally once a day for 15 days. Metformin was also given to another group at a dose of 10 mg/kg of body weight orally once a day for 15 days.
- Anticonvulsant study (PMID: 18276193; animal): Five doses at 1-hour intervals of decoction were administered to curarized rats to assess effects on penicillin-induced epileptic spikes.
- In vitro antioxidant / anti-enzymatic (MDPI Plants, 2023): The methanolic fraction exhibited the strongest antioxidant potential (IC50 39.12 ± 0.53 µg/mL for DPPH and IC50 20.94 ± 0.82 µg/mL for ABTS), and inhibited α-amylase (IC50 188.77 ± 1.67 µg/mL) and AChE (IC50 239.44 ± 0.93 µg/mL).
No human clinical dosing data exist for any preparation of Cestrum nocturnum.
7. Safety Considerations and Toxicology
7.1 General Toxicity Status
All parts of the shrub — the leaves, stems, flowers, and especially the small, white berries — contain toxic alkaloids. These compounds include the glycoalkaloid solanine and atropine-like anticholinergic alkaloids, which are common to the Solanaceae family. Ingestion of any part of the plant can lead to significant poisoning in both humans and animals. Ingestion of C. nocturnum has not been well documented, but there is some reason to believe that caution is in order.
7.2 Human Poisoning: Symptoms and Cases
Clinical features of poisoning by this plant are due to two forms of toxic agents: anticholinergic alkaloid intoxication and glycoalkaloid poisoning from solanine. Acute symptoms include dry mouth, dysphagia, dystonia, tachycardia, and urine retention, followed by hyperthermia with flushed and dry skin. Neurological symptoms occur a little later and include blurred vision, excitement and delirium, headache, and confusion.
Morton documented two cases where children ate handfuls of berries with no significant effects, and another two cases with small amounts of berry ingestion that also caused no adverse effects. In a separate case, a 2-year-old child who ingested green berries over several weeks developed diarrhea, vomiting, and blood clots in the stool, alongside anemia and purpura (skin discoloration caused by subcutaneous bleeding). A solanine alkaloid isolated from the child's stool was found to be hemolytic to human red blood cells.
The most commonly reported issues linked to C. nocturnum are respiratory problems triggered by its scent, and feverish symptoms that develop after ingestion. People with respiratory sensitivities or asthma in particular have reported difficulty breathing, nose and throat irritation, headache, nausea, or other symptoms after exposure to the strong scent of the plant's blossoms.
All parts of the plant are toxic, especially the fruit, and can cause elevated temperature, rapid pulse, excess salivation, and gastritis. The nocturnal fragrance can cause difficulty in breathing, irritation of the nose and throat, sneezing, intense headache, nausea, and dizziness. Respiratory symptoms have also been reported from close proximity to the flowers.
7.3 Role of Chlorogenic Acid in Scent-Related Sensitivity
Some people, especially those with respiratory sensitivities or asthma, have reported difficulty breathing, irritation of the nose and throat, headache, nausea, or other symptoms when exposed to the blossom's powerful scent. Some Cestrum species contain chlorogenic acid, and the presence of this potent sensitizer may be responsible for this effect in C. nocturnum.
7.4 Livestock and Veterinary Toxicity
Toxicity reports of C. nocturnum in livestock in southern Africa mention dullness, tachycardia, rising temperature, suppression of urine, and decrease in respiratory rate as symptoms. Death occurs with coma and slight convulsions. Toxicity of Cestrum for livestock involves several systems. In general, Cestrum species cause liver damage and a clinical-pathological state characterized by acute liver failure of the poisoned animals. Cattle are more susceptible to poisoning by these plants, but there are reports of poisoning in goats and buffaloes as well.
For pets and livestock, consumption of the leaves or berries has been linked to severe gastrointestinal upset, central nervous system issues, and potentially fatal consequences, including hyperexcitability, increased heart rate, and kidney damage.
7.5 Solanine and Anticholinergic Toxicology
Concerns about the plant's toxicity are specifically related to the presence of solanine alkaloids. There is no known definitive treatment for solanine poisoning. It is entirely supportive. Dehydration and electrolyte imbalance is the main feature in solanine poisoning; thus, treatment involves standard measures to correct the fluid and electrolyte imbalance.
7.6 Invasive Weed Status and Environmental Caution
Cestrum nocturnum has become widely naturalized in tropical and subtropical regions throughout the world and is difficult to eradicate. It is classed as a weed in some countries. In Auckland, New Zealand, it has been reported as a seriously invasive weed to the Auckland Regional Council and is under investigation.
7.7 Critical Research Gap
More research is needed, including thorough clinical trials and toxicity assessments, to determine the safety and effectiveness of this plant for specific conditions. The simultaneous presence of pharmacologically interesting bioactive compounds and recognized toxic alkaloids makes the risk-to-benefit ratio of any therapeutic use difficult to evaluate without human clinical data. The plant also contains toxic alkaloids, so caution should be exercised when using it for medicinal purposes.
References
Go back